Brain tumors, including medulloblastoma, are the most common solid pediatric malignancies and the leading cause of childhood cancer-related deaths. Survivors are often left with serious cognitive and neurological disabilities resulting from the effects of both disease and treatment on the developing central nervous system. Hereditary tumor syndromes have helped identify mutations of genes in the Sonic Hedgehog, Wnt and TP53 signaling pathways in subsets of medulloblastoma 1 .
A visual overview of our medulloblastoma copy number data on 201 primary tumors and 11 medulloblastoma cell lines reveals known recurrent regions of large-scale gain and loss, including loss of chromosomes 6, 8, 9q, 10q, 11, 16q and 17p and gains of chromosomes 1q, 7 and 17q (Fig. 1a,b and Supplementary Figs. 1 and 2 online) 2 . Loss of 17p combined with gain of 17q (isochromosome 17q) was identified in B28% (59/212) of medulloblastomas ( Supplementary  Fig. 3 online) 3 . Our SNP array experiments also allow the prediction of inferred loss of heterozygosity (LOH) across the medulloblastoma genome ( Supplementary Fig. 4 online). LOH in medulloblastoma can occur secondary to deletion or in the context of uniparental disomy. We demonstrate that mechanisms leading to LOH in medulloblastoma are chromosome-specific, showing monosomy, uniparental disomy or a mixture of the two mechanisms ( Supplementary Fig. 4 ). The underlying biology driving clonal selection secondary to these extremely large regions of gain and loss is unknown, owing to the difficulty of distinguishing drivers from passengers.
A major strength of high-resolution SNP platforms is their ability to identify extremely focal regions of amplification and deletion. After eliminating known copy number variants (Supplementary Table 1 online), we identified 139 amplifications and 61 homozygous deletions targeting at least one RefSeq gene (Supplementary Table 2 online). The bioinformatic tool GISTIC identified a number of loci as significantly amplified or deleted, including known medulloblastomaassociated genes such as MYC, MYCN, OTX2, TERT, PDGFRA and CDK6 (Fig. 1c,d and Supplementary Table 3 online) 4 . We found amplification of other known oncogenes that were not shown 13  14  15  16  17  18  19  20  21  22   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21 previously to be amplified in medulloblastoma (Table 1a) . We identified 12 recurrent amplifications, including GLI2, encoding a Hedgehog effector (Fig. 1f) , and MYST3, encoding a histone lysine acetyltransferase (Supplementary Table 5 online); 6 of 61 (B10%) homozygous deletions were recurrent (Table 1c) . GISTIC also identified significant regions of deletion targeting loci not previously implicated in medulloblastoma, including genes involved in histone lysine methylation such as EHMT1, L3MBTL3 and SMYD4 ( Fig. 1d and Supplementary Table 3) . Historically, many well-known TSGs were identified through mapping recurrent focal homozygous deletions. Of six recurrent homozygous deletions, only one targeted the coding region of a single RefSeq gene in primary tumors (Table 1c) . These recurrent, focal homozygous deletions of EHMT1 on chromosome 9q34.3 were verified in two primary medulloblastomas (Fig. 2a,b) ; these somatic deletions were not present in matched constitutional DNA (Fig. 2c) . EHMT1 is a SET domain-containing histone lysine methyltransferase that dimethylates H3K9, a predominantly repressive chromatin mark ( Three additional homozygous deletions targeted genes with known roles in histone lysine methylation (total: 5/61 (B8%) homozygous deletions). We found focal homozygous and hemizygous deletions of the Polycomb genes L3MBTL3, L3MBTL2 and SCML2 in a subset of medulloblastomas ( Table 2 ). The MBT (malignant brain tumor) domains of these Polycomb proteins function to bind and interpret the degree of histone lysine methylation, particularly at H3K9 (ref. 6 ). An intragenic homozygous deletion targeted SMYD4, encoding a histone lysine methyltransferase, at 17p13.3, the region most frequently deleted in medulloblastoma ( Table 2 and Supplementary Fig. 3 ). Reanalysis of published data on 244 acute lymphoblastic leukemias and 371 lung adenocarcinomas genotyped on similar platforms did not show any homozygous deletions of EHMT1, L3MBTL3, SCML2 or SMYD4, suggesting that these events are specific to medulloblastoma 7, 8 . Whereas EHMT1 and SMYD4 methylate histone lysine moieties, Jumonji family proteins function as histone lysine demethylases 9 . Our SNP array analysis detected amplification and focal gain of JMJD2B ( Table 2) . Subsequent FISH experiments on a tissue microarray of 88 nonoverlapping medulloblastomas revealed recurrent amplifications (copy number 5-10) of JMJD2B, as well as the known oncogene JMJD2C (Fig. 2f and Table 2) 9 . These proteins demethylate H3K9 and perhaps H3K36 (ref. 10) . We found increased expression of JMJD2C or JMJD2B in 15% and 7.5% of medulloblastomas, respectively (Fig. 2g,h) . Similarly, we found recurrent amplification of the histone lysine acetyltransferase gene MYST3 ( Table 2) , which we predict to result in H3K9 hypomethylation, as H3K9 methylation by EHMT1 is blocked by H3K9 acetylation 11 . SMYD4 showed twofold decreased expression in 30% of medulloblastomas as compared to normal controls (Fig. 2i) . As with the focal genetic events described in Table 2 , we predict that these expression patterns should result in hypomethylation of H3K9.
Although individually uncommon, collectively, these focal genetic events targeting genes that control histone lysine methylation were found in 19% of medulloblastomas ( Table 2) . Copy number aberrations targeting chromatin genes listed in Table 2 were mutually exclusive in our dataset (exact test of a binomial proportion, P ¼ 2.2 Â 10 À16 ), suggesting that they have a common function. Published literature and our results (see below) provide strong links between H3K9 methylation and EHMT1, L3MBTL3, L3MBTL2, SCML2, JMJD2C, JMJD2B and MYST3 (refs. 5, 6, 9, [11] [12] [13] [14] . Lack of nuclear staining for H3K9me2 was seen in 41% of medulloblastomas (Fig. 2e) . Thus, proper control of the histone code, particularly methylation at H3K9, is important in the pathogenesis of some medulloblastomas. There was no enrichment for sex, age group or histological subtype in the medulloblastomas with copy number aberrations in chromatin genes analyzed by SNP array or the non-overlapping group analyzed on the tissue microarray (Supplementary Table 2 ).
EHMT1 is part of the E2F6 complex that preferentially occupies MYC-and E2F-dependent promoters of cells in G 0 rather than in G 1 , suggesting that this complex contributes to silencing in quiescent cells 5 . There is strong causative evidence for E2F-and MYC-dependent transcription in the pathogenesis of human and murine medulloblastoma (Fig. 1e) 15, 16 , and in the proliferation and differentiation of neuronal progenitors in the external germinal layer (EGL) of the cerebellum, a putative cell of origin for a large percentage of medulloblastomas [17] [18] [19] . Other members of the E2F6 complex include HP1, and MBT domaincontaining Polycomb proteins (L3MBTL) 5 . The MBT domain is so named as Drosophila l(3)mbt mutants have failure of neuronal differentiation and develop invasive, malignant neuronal neoplasms in the larval brain, reminiscent of medulloblastoma 20 . The polycomb protein BMI-1, which is overexpressed in most medulloblastomas (Fig. 2j) , binds both E2F6, and L3MBTL3 21 . Bmi1 À/À mice have a hypoplastic cerebellum 22 , and knockdown of BMI1 decreases growth of medulloblastoma in vitro and in vivo 23 .
The medulloblastoma cell line DAOY has a homozygous deletion on chromosome 6 that disrupts three genes: L3MBTL3, SAMD3 and TMEM200A ( Table 2 and Fig. 3a) . This region of chromosome 6 was identified by GISTIC as a significant region of loss in medulloblastoma (Fig. 3b) . If loss of expression of L3MBTL3 provided a clonal advantage, we hypothesized that re-expression of L3MBTL3, but not SAMD3 or TMEM200A, should attenuate the malignant phenotype. Stable re-expression of L3MBTL3 in DAOY results in considerably decreased proliferation as compared to controls when assessed by MTS assay and crystal violet staining (Fig. 3c,d) . Overexpression of L3MBTL3 in the medulloblastoma cell line D283 resulted in only a minor phenotypic change by MTS assay (Fig. 3e) . There was no apparent difference in the incidence of apoptosis in the L3MBTL3 transfectants (Fig. 3f) . Flow cytometry of L3MBTL3-expressing DAOY cells showed a marked reduction in the percentage of cells in G 1 phase of the cell cycle as compared to controls (49% versus 66%, respectively) (Fig. 3g) , and accumulation of cells in S phase (33% versus 21%, respectively), consistent with the known cell cycle effects of ectopic E2F6 expression 24 . Knockdown of Drosophila l(3)mbt results in diminished H3K9 dimethylation of E2F-responsive promotors 14 .
Chromatin immunoprecipitation experiments show that L3MBTL3-transfected DAOY cells have increased H3K9 dimethylation in the promotors of three genes known to be targeted by the E2F6 complex (Fig. 3h ) 5 . This demonstrates that re-expression of L3MBTL3 can attenuate the malignant phenotype of a medulloblastoma cell line, alter the state of H3K9 methylation in known targets of the E2F6 complex and, along with our genetic data, support a critical role for histone lysine methylation in the pathogenesis of medulloblastoma.
Proliferating neural progenitor cells in the outer EGL exit the cell cycle and migrate initially to the inner layer of the EGL, to subsequently form the postmitotic, differentiated neurons of the internal granule cell layer (IGL). EHMT1 is expressed in the developing murine cerebellum at the height of EGL cell proliferation (P7) (Fig. 4a,b) . H3K9me2 staining in the EGL is seen predominantly in the inner, postmitotic layer of the EGL and not in the progenitor cells of the outer EGL (Fig. 4c) . Furthermore, staining for H3K9me2 colocalizes with the cell cycle arrest protein p27 Kip1 (Fig. 4d) , demonstrating that H3K9 dimethylation occurs primarily in postmitotic cells. Although the P7 EGL has exuberant H3K9me2, there is no detectable staining for H3K9me1, and only rare mitotic cells in the EGL stain for H3K9me3 (Fig. 4c,e,f) . Viral transduction of JMJD2C, but not EGFP in cerebellar EGL cells, resulted in high toxicity, as well as diminished H3K9 dimethylation of cerebellar P7 EGL cells in vitro (Fig. 4g) . Viral transduction of NIH 3T3 cells and the medulloblastoma cell line UW228 was not accompanied by the same degree of toxicity, suggesting that toxicity is specific to cell type (Fig. 4h,i) . Consistent with this, treatment of cerebellar EGL cells with the histone deacetylase inhibitor trichostatin A results in H3K9 hyperacetylation, H3K9 hypomethlation and high occurences of cell death 25 . Although the role of H3K9 methylation in cerebellar EGL differentiation has not been directly experimentally addressed, P19 cells cannot undergo retinoic acid-induced terminal neuronal differentiation in absence of HP1, the effector of H3K9 methylation 25 . These data, the known role of H3K9 methylation in embryonic stem cell differentiation, and the known defects in stem/ progenitor cell compartments in L3mbtl3, Jmjd2c, Myst3 and Bmi1 mutant mice are consistent with a model in which proliferative cells in the outer EGL undergo methylation of H3K9 at the time of cell cycle exit, resulting in repression of genes that promote a progenitor cell phenotype 26 . We hypothesize that failure of physiological H3K9 methylation secondary to loss of E2F6 complex members or erasure/blockade of H3K9 methylation results in failure of transcriptional silencing and promotes cellular transformation in the cerebellar EGL.
Our data highlight the genetic heterogeneity of medulloblastoma and support an emerging theme in the literature where mutations of an individual gene are uncommon, but multiple rare genetic events converge on a single common pathway 27 . Although prior successful targeted therapies for cancer focused on a single mutated gene, therapies based on pathway inhibition may be necessary and effective for some cancers 28 . Our results link genetic events in brain cancer with epigenetic control of gene expression and strengthen the link between improper control of the histone code and cancer. The recent identification of small molecules targeting histone lysine methylation 29 , in addition to our genetic and functional data, suggest that manipulating H3K9 methylation should be explored as a targeted therapy for medulloblastoma.
METHODS
Medulloblastoma tumor specimens. We obtained all tumor specimens in accordance with the Research Ethics Board at the Hospital for Sick Children (Toronto, Canada). A total of 201 primary medulloblastomas were obtained as surgically resected, fresh-frozen samples. We obtained tumor specimens from the Co-operative Human Tissue Network (Columbus, OH), the Brain Tumor Tissue Bank (London, Canada) and from our collaborators. Additional clinical details are available in the Supplementary Note online.
100K and 500K GeneChip mapping arrays. Medulloblastoma samples were processed and hybridized to Affymetrix SNP arrays at the Centre for Applied Genomics (TCAG) at the Hospital for Sick Children. We genotyped genomic DNA samples isolated from primary medulloblastomas and cell lines using the Affymetrix 50K Hind 240 and 50K Xba 240, or the 250K Nsp and 250K Sty GeneChip Mapping arrays as directed by the manufacturer. Briefly, 250 ng of DNA was digested with HindIII, XbaI, NspI or StyI (NEB), adaptor-ligated and PCR-amplified using a single primer with AmpliTaq Gold (Applied Biosystems). Amplified PCR products were pooled, concentrated and fragmented with DNase I. Products were subsequently labeled, denatured and hybridized overnight to the respective arrays. Arrays were washed using an Affymetrix fluidics station and scanned using the GeneChip Scanner 3000. We generated CEL files using the Affymetrix GeneChip Operating Software (GCOS) 3.0. See Supplementary Methods online for additional details.
SNP array data processing. Affymetrix CEL files were extracted using the Affymetrix Data Transfer Tool (version 1.1.0). For SNP genotyping, we used the BRLMM Analysis Tool (version 1.0) for individual array platforms using default parameters. Copy number and loss of heterozygosity (LOH) analyses were done using both dChip 2006 and CNAG 2.0. In dChip, we normalized arrays by invariant set normalization and computed signal intensities using PM/MM model-based expression. Raw copy number data was computed using 100 normal control samples as a reference (provided by S.W.S.) and inferred copy numbers were predicted using the hidden Markov model (HMM). We carried out LOH analysis using the HMM considering haplotype method, removing haplotypes consistent with Z10% of reference samples. In CNAG, nonself analysis was done automatically with the same reference samples as above using a maximum of ten reference samples of the same sex per analysis. Inferred copy number changes and LOH were predicted using the HMM with default parameters.
To identify homozygous deletions, we used the following criteria: (i) Z3 contiguous SNPs, (ii) size range 1 kb-10 Mb and (iii) mean dChip/CNAG HMM copy number r0 or mean dChip raw copy number r0.4. To identify amplifications, we used the following criteria: (i) Z5 contiguous SNPs, (ii) size range 10 kb-10 Mb and (iii) mean dChip/CNAG HMM copy number Z5. Recurrent, focal single copy losses were reported using the following criteria: (i) Z3 samples with overlapping interstitial loss (CNAG HMM copy number ¼ 1) and (ii) size range of individual losses 10 kb-5 Mb.
To exclude abnormalities associated with known segmental duplications (LCRs), we compared amplifications and deletions to the LCRs detected in the Human Genome Segmental Duplication Database. Similarly, all amplifications and deletions were compared to known characterized structural variants through comparison with known copy number variants (CNVs) using the Database of Genomic Variants (February 2007). Regions of genomic gain or loss overlapping with known CNVs were eliminated.
To identify regions of statistical significance, raw copy number data was first segmented using GLAD (Gain and Loss Analysis of DNA) and probable CNVs were eliminated on the basis of their overlap with known, recurrent (Z2 samples) CNVs described in the HapMap and POPGEN control populations and/or the Ontario control population. We then analyzed filtered segmented copy number data with GISTIC (Genomic Identification of Significant Targets In Cancer) in GenePattern using default parameters.
Fluorescence in situ hybridization. FISH for JMJD2 family members was carried out on a medulloblastoma tissue microarray as previously published 30 . BACs used for probes included RP11-1082E7 (JMJD2C, 9p24.1), RP11-235C23 (9q31.2 control), RP11-3214K1 (JMJD2B, 19p13.3), RP11-927F22 (19q13.32 control), RP11-105H7 (19q13.32 control), RP11-5C19 (JMJD2A, 1p34.1), RP11-54H19 (1q22 control) and RP11-336K24 (1q22 control).
Chromatin immunoprecipitation (ChIP). Chromatin immunoprecipiation of modified histones was done using the Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore) according to the manufacturer's instructions. Briefly, 10 6 medulloblastoma cells were fixed in culture medium with 1% (vol/vol) formaldehyde (VWR International) at 37 1C for 10 min, washed twice on ice with cold PBS and collected by centrifugation at 2,000 rpm for 4 min at 4 1C. Cells were lysed in SDS lysis buffer for 10 min on ice, sonicated and cleared by centrifugation at 13,000 rpm for 10 min at 4 1C. Cell supernatants were diluted in ChIP dilution buffer and pre-cleared for 30 min with Protein A Agarose/ Salmon Sperm DNA slurry at 4 1C before immunprecipitation with appropriate antibodies overnight at 4 1C. Immune complexes were captured by incubation with Protein A Agarose/Salmon Sperm DNA slurry for 1 h at 4 1C, before 5 min washes with low salt buffer, high salt buffer, and LiCl buffer, and two 5 min washes with TE buffer. Histone complexes were eluted from primary antibodies by two successive 15-min incubations with elution buffer (1% SDS, 0.1M NaHCO 3 ). Histone-DNA cross-links were reversed by addition of 5M NaCl and heating at 65 1C for 4 h, followed by proteinase K digestion for one hour at 45 1C. DNA was then recovered by phenol/chloroform extraction and ethanol precipitation with glycogen. Resulting DNA pellets were washed once with 70% ethanol and resuspended in TE buffer. To assess the levels of H3K9me2 at promoters of candidate genes, we carried out end-point PCR reactions using primers targeting the promoter regions of MYC, TK1 and CDC25A.
Note: Supplementary information is available on the Nature Genetics website.
